Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Research Council grant · Running

Smart Nanoparticles 4D Brain-Targeting Nanomedicines for Treating Neurodegeneration

Coordinator
Technion - Israel Institute of Technology, Israel
Runs
1 May 2023 to 30 April 2028
Status
Running
EU funding
€2.0m
Total cost
€2.0m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101089009

What the project is doing

In the project's own words, from its summary on CORDIS.

Aging, Aging, genetic, and environmental factors have increased the prevalence of patients with neurodegenerative brain conditions, with limited treatment modalities. One prerequisite for effective brain treatments is the ability to target next-generation medications, including RNA and protein drugs, to specific neurons and brain regions. Nanotechnology platforms offer new therapeutic avenues for targeting drugs to organs and cells; their implementation in neurodegenerative diseases is nascent.

In this research program, we aim to advance far beyond the state-of-the-art and elucidate the molecular and structural characteristics for designing nanotechnology drugs that target and treat brain neurodegeneration. In preliminary studies, we show that the blood-brain-barrier (BBB) overexpresses disease-specific receptors during neurodegeneration, which enable targeted nanoparticles to cross the BBB and penetrate neurons.

Albeit these findings, the magnitude, mechanism, and nanotechnological molecular pattern for brain targeting are lacking. To address this fundamental gap, we will use advanced computation and engineering concepts to develop 4D-brain-targeting nanoparticles, that cross the BBB intact to target specific neuronal populations and brain regions. Robotic synthesis, coupled with active learning algorithms will be used to construct nanoparticles with combinations of targeting moieties on their surface and evaluate their neuronal specificity.

Supported microfluidic BBB apparatus will be used to screen the nanoparticles ability to target and cross the BBB. A track-and-seek radar system will locate the nanoparticles in the brain, directing localized robotic biopsy of the nanoparticles in the destination cells in the brain. To connect our findings to future clinical implementation, fMRI will be used to record the therapeutic activity of the nanoparticles in the brain.

This program will provide the community with essential findings to allow brain-targeted therapeutics.

Topics

Who is involved

OrganisationCityCountryRole
Technion - Israel Institute of TechnologyHaifaIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI